Healthcare -
Biotechnology - NASDAQ - US
$ 19.26
-8.4 %
$ 242 M
Market Cap
-0.73
P/E
1. INTRINSIC VALUE
Balance Sheet
Cidara Therapeutics, Inc.
| Current Assets | 211 M |
| Cash & Short-Term Investments | 190 M |
| Receivables | 1.69 M |
| Other Current Assets | 19.2 M |
| Non-Current Assets | 4.06 M |
| Long-Term Investments | 0 |
| PP&E | 3.96 M |
| Other Non-Current Assets | 96 K |
| Current Liabilities | 49.6 M |
| Accounts Payable | 3.61 M |
| Short-Term Debt | 1.64 M |
| Other Current Liabilities | 44.3 M |
| Non-Current Liabilities | 1.93 M |
| Long-Term Debt | 0 |
| Other Non-Current Liabilities | 1.93 M |
EFFICIENCY
Earnings Waterfall
Cidara Therapeutics, Inc.
| Revenue | 1.28 M |
| Cost Of Revenue | 84.9 M |
| Gross Profit | -83.6 M |
| Operating Expenses | 92.5 M |
| Operating Income | -176 M |
| Other Expenses | -6.28 M |
| Net Income | -170 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Cidara Therapeutics, Inc.
| Net Income | -170 M |
| Depreciation & Amortization | 233 K |
| Capital Expenditures | -129 K |
| Stock-Based Compensation | 3.91 M |
| Change in Working Capital | -13.9 M |
| Others | -30.2 M |
| Free Cash Flow | -177 M |
Wall Street Analysts Price Targets
Cidara Therapeutics, Inc.
Wall Street analysts predict an average 1-year price target for CDTX of $35 , with forecasts ranging from
a
low of
$24 to a high of $46 .
CDTX Lowest Price Target
Wall Street Target
24 USD
24.61%
CDTX Average Price Target
Wall Street Target
35 USD
81.72%
CDTX Highest Price Target
Wall Street Target
46 USD
138.84%
4. DIVIDEND
ANALYSIS
CDTX does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Cidara Therapeutics, Inc.
Sold
0-3 MONTHS
75.5 K USD 2
3-6 MONTHS
0 USD 0
6-9 MONTHS
21.3 K USD 2
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
106 K USD 1
9-12 MONTHS
7. News
Cidara Therapeutics: Strong Buy On Imminent Data Readout For Lead Flu Candidate
We initiate coverage on Cidara Therapeutics with a Strong Buy rating due to its strategic pivot to antiviral CD388 and promising Phase 2b trial data. Rezafungin's successful approval and divestiture to Mundipharma validate Cidara's development capabilities and free resources for advancing CD388. CD388 shows potential for season-long influenza protection, with promising Phase 2a data and a well-funded Phase 2b trial targeting high-risk patients.
seekingalpha.com
- 2 weeks ago
Cidara Therapeutics Announces Promotion of Nicole Davarpanah to Chief Medical Officer and Corrina Pavetto to SVP, Clinical Development
SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that Nicole Davarpanah, M.D., J.D. has been promoted to chief medical officer (CMO), and Corrina Pavetto has been promoted to senior vice president, clinical development, effective May 1, 2025.
globenewswire.com
- 2 weeks ago
Are You Looking for a Top Momentum Pick? Why Cidara Therapeutics (CDTX) is a Great Choice
Does Cidara Therapeutics (CDTX) have what it takes to be a top stock pick for momentum investors? Let's find out.
zacks.com
- 2 weeks ago
Cidara Therapeutics to Participate in The Citizens Life Sciences Conference
SAN DIEGO, April 30, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that company management will participate in The Citizens Life Sciences Conference. Details are as follows: Event: The Citizens Life Sciences Conference Date: Wednesday, May 7, 2025 Time: 11:00 AM ET Format: Presentation Webcast: https://wsw.com/webcast/jmp65/cdtx/1686102 A replay of the presentation will be available in the Investors section on the Company's website at www.cidara.com.
globenewswire.com
- 2 weeks ago
Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors
FLORHAM PARK, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced the appointment of Ted Schroeder to its Board of Directors.
globenewswire.com
- 1 month ago
Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced that the Compensation and Human Capital Committee of its Board of Directors (Compensation Committee) granted Timothy Alefantis, a new employee, a non-qualified stock option award and restricted stock units (RSUs) for an aggregate of 27,000 shares of its common stock, pursuant to the Cidara Therapeutics, Inc. 2020 Inducement Incentive Plan, as amended (the Inducement Plan), with a grant date of March 31, 2025. The stock option has an exercise price of $21.54 per share, which is equal to the closing price of Cidara's common stock on the grant date. The shares subject to the option will vest over four years, with 25% of the shares vesting on the one-year anniversary of the vesting commencement date and the balance of the shares vesting in a series of 36 successive equal monthly installments thereafter. All RSUs vest in four equal annual installments, with 1/4 vesting on each of the first, second, third and fourth anniversaries of the Quarterly Vesting Date (as defined below) that occurs during the calendar quarter that includes the date of grant. “Quarterly Vesting Date” means March 10, June 10, September 10 or December 10. The awards are subject to the award holder's continuous service through each vesting date and to the terms and conditions of the Inducement Plan and the standard forms of grant agreements thereunder.
globenewswire.com
- 1 month ago
Cidara Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced that company management will participate in the 24th Annual Needham Virtual Healthcare Conference. Details are as follows: Event: 24th Annual Needham Virtual Healthcare Conference Date: Wednesday, April 9, 2025 Time: 11:00 AM ET Format: Presentation Webcast: https://wsw.com/webcast/needham146/cdtx/2261559 A replay of the presentation will be available in the Investors section on the Company's website at www.cidara.com.
globenewswire.com
- 1 month ago
Wall Street Analysts Predict a 64.5% Upside in Cidara Therapeutics (CDTX): Here's What You Should Know
The consensus price target hints at a 64.5% upside potential for Cidara Therapeutics (CDTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
zacks.com
- 1 month ago
Cidara Therapeutics to Participate in World Health Organization Meeting on H5N1 Influenza Preparedness and Response
SAN DIEGO, March 19, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced participation in the “Other pharmaceuticals as preventive tools” panel at a World Health Organization (WHO) global meeting on H5N1 influenza preparedness and response. The meeting, titled “What research is important to prepare and respond to H5N1 influenza outbreaks,” will be held virtually on March 19, 2025, from 1:00-7:15pm Central European Time (CET)/5:00-11:15am Pacific Time (PT), and the panel discussion will take place from 6:30-7:00 pm CET/10:30-11:00am PT.
globenewswire.com
- 2 months ago
Cidara Therapeutics Announces Two Presentations on CD388 in Influenza at International Conference on Antiviral Research (ICAR) 2025
SAN DIEGO, March 18, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced two upcoming presentations at the 38th International Conference on Antiviral Research (ICAR). The conference takes place from March 17-21, 2025 in Las Vegas, Nevada.
globenewswire.com
- 2 months ago
Cidara Therapeutics Announces Publication of CD388 Preclinical Data in Nature Microbiology
Data highlights potential of CD388 as a potent, universal antiviral for influenza prevention regardless of immune status
globenewswire.com
- 2 months ago
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
SAN DIEGO, March 06, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today reported financial results for the fourth quarter and full year ended December 31, 2024 and provided recent business updates.
globenewswire.com
- 2 months ago
8. Profile
Summary
Cidara Therapeutics, Inc. CDTX
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 242 M
Dividend Yield
0.00%
Description
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.
Contact
6310 Nancy Ridge Drive, San Diego, CA, 92121
https://www.cidara.com
IPO
Date
April 15, 2015
Employees
38
Officers
Ms. Corrina Pavetto
Senior Vice President of Clinical Development
Mr. Shane M. Ward J.D.
Chief Operating Officer & Corporate Secretary
Dr. Leslie Tari Ph.D.
Chief Scientific Officer
Ms. Allison Lewis CCP, SPHR
Senior Vice President of People & Culture
Dr. Nicole Davarpanah J.D., M.D.
Chief Medical Officer & SVice President of Translational Research & Development
Mr. Frank L. Karbe M.B.A.
Chief Financial Officer
Dr. Preetam Shah M.B.A., Ph.D.
Principal Accounting Officer
Mr. Jim Beitel M.B.A.
Chief Business Officer
Dr. Jeffrey L. Stein Ph.D.
President, Chief Executive Officer & Executive Director
Dr. Kevin M. Forrest Ph.D.
Founder & Chief Strategy Officer